Navigation Links
Rituximab in Medical News

Study shows that maintenance rituximab is useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. ...

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

...2008 for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The following serious adverse reactions have been associated with TREANDA in clinical trials: myelosuppressi...

Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say

...iagnosed, untreated patients. Both epratuzumab and rituximab are monoclonal antibodies that attach to proteins ...ound on the outside surface of B cells -- CD20 for rituximab and CD22 for epratuzumab. They are also used as im...mmunity or are malignant," Dr. Micallef says. rituximab is approved for use by the Food and Drug Administr...

Two targeted therapies likely better than one in patients with aggressive lymphoma

...iagnosed, untreated patients. Both epratuzumab and rituximab are monoclonal antibodies that attach to proteins ... found on the outside surface of B cells CD20 for rituximab and CD22 for epratuzumab. They are also used as im...oimmunity or are malignant," Dr. Micallef says. rituximab is approved for use by the Food and Drug Administr...

Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease

...ical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also...

UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

...ical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

...the investigational compound, ofatumumab, in advanced stage blood cancer. "Ofatumumab, a novel CD20 mAB, is active regardless of prior rituximab exposure in patients with fludarabine-and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)." Dr. W. Wierda, M...

New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas

..." Also new to the NCCN Guidelines is information regarding the potential for viral reactivation in hepatitis positive patients being treated with rituximab (Rituxan(R), Genentech, Inc.). Dr. Zelenetz explained Hepatitis B can reactivate with immunosuppression. "More than 1 million people in the Unit...

Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma

...ry follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall sur... disease relapse. Previous trials have showed that rituximab plus chemotherapy improves overall survival in the...lone. However, it has not been clear if continuing rituximab treatment beyond the completion of chemotherapy fu...

Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma

... 2009 in the Annals of Oncology demonstrating that rituximab followed by single agent Zevalin (ibritumomab tiux...imately 1 week later received a second infusion of rituximab followed by single dose of Yttrium-90 Zevalin. ...l non- Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicat...
Rituximab in Medical Technology

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that ...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

SEATTLE, Nov. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has published in the November 1, 2008 issue the results of a study authored by Samual Jacobs et al. investigating the use of short-course CHOP-R followe...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

Study Reports 92 Percent Response Rate to Combination Treatment FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-c...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs. 11%), ORR ...rogression (TTP) (13.2 vs. 8.1 months) compared to rituximab alone in relapsed indolent NHL Phase II; AZA I06- Pixantrone plus fludarabine, and rituximab (FPD-R regimen) produces high CR/CRu (70%) and ORR...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen and TRISENOX(R) (arsenic trioxide) injection, approved for the treatment of patients with relapsed or refractory acu...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...e III trial investigating adjuvant treatment with everolimus (RAD001) in poor-risk patients with DLBCL who achieved complete remission with first-line rituximab combined with chemotherapy. This worldwide study will evaluate the potential of everolimus to extend disease-free survival in patients with DLBCL. The...

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)

...whom had received an average of 6.5 prior treatments, including at least one fludarabine-containing regimen. All patients had also previously received rituximab or other anti-CD20 therapies an average of three times, either as a single agent or as part of a combination regimen. Of the 24 patients with genetic ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

...e14591; Publication only. Non-Hodgkin's Lymphoma Kingsley E, et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade I-II, follicular Non-Hodgkin's Lymphoma (FL). Abstract #8582; Poster Board #S11; Lymphoma and Plasma Cell Disor...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

...nical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

...dangerous immunosuppression for the patient. "This is a very selective compound for B-cells, and it could represent an important alternative to rituximab therapy for the treatment of B-cell NHL. Other obvious applications include autoimmune disorders such as rheumatoid arthritis and lupus, and Pharmacyc...
Rituximab in Biological News

Galiximab in combination with rituximab in patients with previously untreated follicular lymphoma

Lugano, Switzerland June 7, 2008 The Cancer and Leukemia Group B (CALGB) today announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, ...

Cancer and arthritis therapy may be promising treatment for diabetes

...ntibody is no longer administered, the researchers said. The antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in mutant mice indicat...ere predisposed to diabetes and had the human version of CD20, the molecule rituximab targets, on the surface of their B cells. The researchers tested a mous...

Ireland Cancer Center researchers advance stem cell gene therapy

... and poster presentations. The presentations include: Dr. Hillard Lazarus and colleagues presented significant findings that treatment with rituximab before transplantation results in cure rate and overall survival in patients undergoing autologous stem cell transplantation for Diffuse Large B-Cell ...

Knocking out survival protein could aid leukemia treatment

...his protein in CLL cells and suggest that this should enhance the action of rituximab and perhaps other agents as well." rituximab is an antibody-based drug that targets CLL and ALL cells and causes the cel...

GlycoFi announces the first production of antibodies with human glycosylation in yeast

...d in Nature Biotechnology, the researchers used several glyco-engineered yeast cell lines to produce a library of glycoforms of the anti-CD20 antibody rituximab and to compare their receptor binding properties to the mammalian-derived commercial counterpart, Rituxan®. The polypeptide backbone of each of the an...
Rituximab in Biological Technology

Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit

... and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen and TRISENOX((R)) (arsenic trioxide) injection, approved for the treatment of patients with relapsed or refractory a...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

...ical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also...

Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting

... demonstrated in assays against the NHL-derived DoHH2 cell line, that Trubion's SCORPION multispecific therapeutic was 100 times more potent than both rituximab and the combination of the individual mono-specific SMIP molecules against the respective CD79B and HLA-DR targets. This enhanced potency was shown to...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

...wgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated app... with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe...

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

...-Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. Zevalin is also indicat...ll non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicat...n symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin adminis...

Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug

...grade or follicular B-cell non- Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. ZEVALIN is also indicated, under accelerated app... with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 ZEVALIN administration results in severe...

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

...ws for Calcium Influx Which Induces Streamers. Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX. Ofatumumab is an inves...

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma

...or follicular B-cell non- Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. The Zevalin therapeutic regimen has been given a... with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe...

Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy

...-Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. Zevalin is also indicat...ll non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicat...n symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin adminis...

FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion

...-Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. Zevalin is also indicat...ll non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicat...n symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin adminis...
Rituximab in Biological Dictionary

Monoclonal Antibody

...noclonal antibodies described above was invented by ... The immunogenicity of the monoclonal antibody itself is a concern because of how ... rituximab is an IgG monoclonal antibody , and has an Fc receptor. ... Monoclonal antibodies (MAbs for short) are an essential part of a molecular biol...
Other Tags
(Date:9/1/2015)... ... September 01, 2015 , ... ... options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor ... , Based in San Francisco, Doctor On Demand provides immediate access to Board ...
(Date:9/1/2015)... ... 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and founder ... firm’s success in the hair care and distribution industry through her combination of ... be providing “Look and learn” live demonstrations, as well as promoting her new ...
(Date:9/1/2015)... Melbourne, Florida (PRWEB) , ... ... ... Association of Professional Background Screeners (NAPBS®) has announced that Edge Information ... audit conducted by the Background Screening Credentialing Council (BSCC). , “Achieving ...
(Date:9/1/2015)... Winston-Salem, NC (PRWEB) , ... September 01, 2015 , ... ... (Science, Technology, Engineering and Math) disciplines since its inception more than 35 years ago. ... and high-school students and their teachers - and, not just those intent on pursuing ...
(Date:9/1/2015)... ... 2015 , ... Royal River Natural Foods, a locally-owned independent natural health store ... 19 years and found that, among those who had a stroke, people who used ... part of the September 2015 issue of “Natural Insights for Well Being,” which Royal ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
(Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
Other Contents